APEIRON Respiratory Therapies

APEIRON Respiratory Therapies, a privately-held biotech company focused on the discovery and development of treatments for respiratory diseases, was spun off from APEIRON Biologics AG in early 2022 to continue the development of APN01. AResT is a 100% subsidiary of invIOs GmbH, concentrating on the development of APEIRON Biologics' immuno-oncology assets.